Prevention and Treatment of Experimental Estrogen Receptor-Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-08-0040
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

The Combination of Tamoxifen and the Rexinoid LG100268 Prevents ER-Positive and ER-Negative Mammary Tumors in P53-Null Mammary Gland Mice

Cancer Prevention Research
MedicineCancer ResearchOncology
2012English

The SERM, Arzoxifene, and the Rexinoid, LG100268, Cooperate to Prevent Estrogen Receptor-Positive and -Negative Breast Cancer as Well as Colon Cancer.

English

CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer

Scientific Reports
Multidisciplinary
2020English

Increased Estrogen Receptor Cx Expression During Mammary Carcinogenesis

Clinical Cancer Research
Cancer ResearchOncology
2005English

The Synthetic Triterpenoid, CDDO-Me, Modulates the Proinflammatory Response toIn VivoLipopolysaccharide Challenge

Journal of Interferon and Cytokine Research
MedicineVirologyImmunologyCell Biology
2010English

Prevention of Prostate Cancer With Oleanane Synthetic Triterpenoid CDDO-Me in the TRAMP Mouse Model of Prostate Cancer

Cancers
Cancer ResearchOncology
2011English

Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription

PLoS ONE
Multidisciplinary
2009English

N-Methyl-N-Nitrosourea-Induced Mammary Carcinogenesis Is Promoted by Short-Term Treatment With Estrogen and Progesterone Mimicking Pregnancy in Aged Female Lewis Rats

Oncology Reports
MedicineCancer ResearchOncology
2007English

Neonatal Experiences Differentially Influence Mammary Gland Morphology, Estrogen Receptor Protein Levels, and Carcinogenesis in BALB/c Mice

Cancer Prevention Research
MedicineCancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy